HEU-EFS Harmonised Approach to Early Feasibility Studies for Medical Devices in the European Union
- Coordinator
- Universita Commerciale Luigi Bocconi, Italy
- Runs
- 1 October 2023 to 30 September 2027
- Status
- Running
- EU funding
- €10.5m
- Total cost
- €19.1m
- Partners
- 41 organisations in 13 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101112185
What the project is doing
In the project's own words, from its summary on CORDIS.
EU Regulations on medical devices (MDs), in-vitro diagnostics, and Health Technology Assessment envisage a harmonised lifecycle approach for clinical evidence generation of MDs. To be effective this approach requires evidence generation plan to be developed since early stages of product development, by engaging all relevant stakeholders. At present, in the EU there are no standardized procedural frameworks/guidelines/common reference standards for Early Feasibility Studies (EFS), clinical investigations allowed by ISO 14155:2020 conducted early in the development aiming to inform the product development.
The ambition of the HEU-EFS project is to develop a harmonised framework for the EU EFS Program, as one integrated step of evidence generation cycle. Project objectives include: (1) conducting research/analysis on state of play (i.e., characteristics, challenges, impacts) of pre-market programs for MDs, including EFS; (2) building a sustainable network of stakeholders at EU/national level to promote/support EFS implementation; (3) developing a sound, widely applicable, harmonised EU methodology and formulating recommendations to uptake EFS; (4) undertaking pilots to test the proposed framework; (5) developing instruments to monitor the EFS performance; and (6) implementing a dedicated, sustainable, open access online portal dedicated to EFS methodological framework, best practices and network.
To achieve these goals, the HEU-EFS consortium has been designed including a wide range of relevant stakeholders: research organisations, HTA bodies, patient organizations, healthcare providers, SMEs (including health technology developers, legal experts, and a CRO), and 6 major private companies that are part of a pre-identified industry consortium. An Advisory Board made of competent authorities, notified bodies, medical and biomedical engineering professional associations, networks and industry trade association will collaborate to the success of the initiative.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universita Commerciale Luigi Bocconi | Milano | Italy | Coordinator |
| Abbott Vascular International | Machelen | Belgium | Participant |
| Edwards Lifesciences Belgium BV | Dilbeek | Belgium | Participant |
| Forum Des Patients Europeens | Bruxelles / Brussel | Belgium | Participant |
| St Jude Medical Coordination Center | Zaventem | Belgium | Third party |
| Edwards Lifesciences SARL | Nyon | Switzerland | Third party |
| Synthes GmbH | Oberdorf Bl | Switzerland | Participant |
| Edwards Lifesciences GmbH | Garching B. Munchen | Germany | Third party |
| Philipps Universitaet Marburg | Marburg | Germany | Participant |
| Qurasoft GmbH | Koblenz | Germany | Participant |
| Region Syddanmark | Vejle | Denmark | Participant |
| Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer | Barcelona | Spain | Participant |
| Hospital Clinic De Barcelona | Barcelona | Spain | Third party |
| Medtronic Iberica SA | Madrid | Spain | Third party |
| Abbott France | Rungis Cedex | France | Third party |
| Assistance Publique Hopitaux De Paris | Paris | France | Participant |
| Carmat | Velizy-Villacoublay | France | Participant |
| Edwards Lifesciences SAS | Guyancourt | France | Third party |
| Sofradim Production Sasu | Trevoux | France | Third party |
| Global Heart Hub Company Limited by Guarantee | Galway | Ireland | Participant |
| The Provost, Fellows, Foundation Scholars & the Other Members of Board, of the College of the Holy & Undivided Trinity of Queen Elizabeth Near Dublin | Dublin | Ireland | Participant |
| University of Galway | Galway | Ireland | Participant |
| Abbott Medical Italia SRL | Sesto San Giovanni - Mi | Italy | Third party |
| Agenzia Nazionale per I Servizi Sanitari Regionali | Roma | Italy | Participant |
| Fondazione Policlinico Universitario Agostino Gemelli Irccs | Roma | Italy | Participant |
| Meditrial S.r.l. | Roma | Italy | Participant |
| Newronika SpA | Milano | Italy | Participant |
| W.l. Gore & Associati S.r.l. | Verona | Italy | Participant |
| Abbott BV | Hoofddorp | Netherlands | Third party |
| Edwards Lifesciences BV | Breda | Netherlands | Third party |
| Idris Oncology B.v. | Leiden | Netherlands | Participant |
| Medtronic Bakken Research Center B.v. | Maastricht | Netherlands | Participant |
| Philips Medical Systems Nederland BV | Best | Netherlands | Participant |
| W L Gore & Associates BV | Tilburg | Netherlands | Third party |
| Folkehelseinstituttet | Oslo | Norway | Participant |
| Abbott Laboratorios Lda | Amadora | Portugal | Third party |
| Abbott Laboratories Limited | Berkshire | United Kingdom | Third party |
| Edwards Lifesciences Llc | Irvine California | United States | Third party |
| Evalve, Inc | Wilmington | United States | Third party |
| St Jude Medical Business Services Inc | Wilmington | United States | Third party |
| St Jude Medical Cardiology Division Inc | Wilmington Delaware | United States | Third party |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI